General Information of Drug (ID: DR2502)
Drug Name
Baricitinib
Synonyms
Baricitinib; Gestakadin; ISP4442I3Y; J-503551; LY 3009104; LY-3009104; LY3009104; Milli-Anovlar; Milligynon; Miniphase; Monogest; Aygestin; Norethindrone 17-acetate; Norethindrone acetate; Norethindrone acetate [USP]; Norethisteron acetate; Norethisterone acetate; Norethynyltestosterone acetate; Norethysterone acetate; Norlutin A; Norlutin acetate; Norlutine acetate; Orlutate; Primolut-Nor; Progylut; SH 420; olumiant; (17-alpha)-Norethindrone acetate; 1187594-09-7; 17alpha-Ethynyl-19-nortestosterone acetate; 19-Norethindrone acetate; 19-Norethisterone acetate; 19-Norethynyltestosterone acetate; 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile; 3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-; 51-98-9; Baricitinib (LY3009104, INCB028050); C16H17N7O2S; ENTA; INCB 028050; INCB 28050; INCB-028050; INCB028050; UNII-9S44LIC7OJ; UNII-ISP4442I3Y
Indication Rheumatoid arthritis [ICD11: FA20] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 371.4 Topological Polar Surface Area 129
Heavy Atom Count 26 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 7
Cross-matching ID
PubChem CID
44205240
PubChem SID
85205106 ; 89960290 ; 103932354 ; 135313591 ; 136946415 ; 137856279 ; 144115683 ; 152258684 ; 160647521 ; 160703522 ; 162009736 ; 162011992 ; 162108950 ; 163312339 ; 164045123 ; 164194014 ; 170501894 ; 172087008 ; 172918187 ; 174006690 ; 174526483 ; 176250838 ; 185979207 ; 189561494 ; 198946894 ; 203105586 ; 208265518 ; 215785530 ; 223366123 ; 223375538 ; 223630418 ; 223705259 ; 224310310 ; 227140190 ; 244162815 ; 249733389 ; 249814474 ; 249816401 ; 252110203 ; 252160600 ; 252214958 ; 252443897 ; 252451786 ; 252553656
ChEBI ID
CHEBI:95341
CAS Number
1187594-09-7
TTD Drug ID
D0Y7IC
Formula
C16H17N7O2S
Canonical SMILES
CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChI
1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
InChIKey
XUZMWHLSFXCVMG-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Baricitinib M1 DM016569
129132345
Oxidation - Hydroxylation 1 [4]
Baricitinib M2 DM018975 N. A. Oxidation - Hydroxylation 1 [4]
Baricitinib M3 DM016194
57868834
Oxidation - N-dealkylation 1 [4]
Baricitinib M5 DM016710
145706607
Hydrolysis - Hydrosis 1 [4]
Baricitinib M6 DM016836
156596842
Oxidation - Oxidation 1 [4]
Baricitinib M4 DM016076
44231254
Oxidation - Dealkylation 2 [4]
Baricitinib M7 DM016837
156596930
Oxidation - Oxidation 2 [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR014155 Baricitinib Baricitinib M1 Oxidation - Hydroxylation Unclear [4]
MR014157 Baricitinib Baricitinib M5 Hydrolysis - Hydrosis Unclear [4]
MR014158 Baricitinib Baricitinib M3 Oxidation - N-dealkylation Unclear [4]
MR014171 Baricitinib Baricitinib M6 Oxidation - Oxidation Unclear [4]
MR014173 Baricitinib Baricitinib M2 Oxidation - Hydroxylation Unclear [4]
MR014156 Baricitinib M1 Baricitinib M4 Oxidation - Dealkylation Unclear [4]
MR014172 Baricitinib M6 Baricitinib M7 Oxidation - Oxidation Unclear [4]
⏷ Show the Full List of 7 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
References
1 Baricitinib was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 FDA label of Baricitinib. The 2020 official website of the U.S. Food and Drug Administration.
3 DrugBank(Pharmacology-Metabolism):Baricitinib
4 High resolution mass spectrometry-driven metabolite profiling of baricitinib to report its unknown metabolites and step-by-step reaction mechanism of metabolism

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.